Logo

Ingenium to Create Animal Models for Grnenthal

Feb 25, 2004

NEW YORK, Feb. 25 (GenomeWeb News) - Ingenium Pharmaceuticals will develop animal models with defined gene mutations for Gr nenthal, the German companies said today.

 

Ingenium, of Munich, will utilize its Ingenotyping technology, which enables it to create in four months a series of mammalian models carrying genetic alterations in any target gene of interest, according to the company.

 

Gr nenthal, based in Aachen, plans to use the animal models resulting from the collaboration to validate targets for the treatment of pain.

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.